Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Leiden – page 138

1 938 clinical trials in Leiden, The Netherlands across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Leiden at a glance
1 938
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

1 938 trials in Leiden

Open in trial search

Hormone-dependent prostate cancer

Not recruiting

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Oesophageal squamous cell carcinoma

Not recruiting

Study on Bintrafusp Alfa with Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bintrafusp Alfa
  • Sponsor:Amsterdam UMC Stichting

Psoriatic arthropathy

Not recruiting

Study to Predict Tofacitinib Effectiveness in Psoriatic Arthritis Patients Using Tofacitinib, Methotrexate, and Folic Acid

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Universitair Medisch Centrum Utrecht

Eosinophilic oesophagitis

Not recruiting

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Crohn's disease

Not recruiting

Long-term study of upadacitinib tablets for adults with Crohn's disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects of Riliprubart for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Cardiac operation

Not recruiting

Study on Preventing Acute Kidney Injury in Cardiac Surgery Patients Using Dapagliflozin

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Amsterdam UMC Stichting

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Non-small cell lung cancer

Not recruiting

Study Comparing Sacituzumab Govitecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Gilead Sciences Inc.

Focal segmental glomerulosclerosis+1

Not recruiting

Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:R3R01
  • Sponsor:River 3 Renal Corp.

Myasthenia gravis

Not recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Leiden

What the registry says about research in the country

01 Infectious Diseases Research

Innovative studies focusing on viral infections including trials evaluating vaccines against yellow fever, influenza, and mpox. Research includes assessment of antibody responses and vaccine effectiveness in different populations.

  • Influenza vaccine efficacy in elderly
  • Yellow fever prophylaxis
  • Mpox booster vaccination

Particular emphasis on preventive strategies and immune response evaluation.

02 Neurological Studies

Comprehensive research targeting neurological conditions, including investigations into Parkinson's disease treatments and neural response patterns. Studies examine innovative therapeutic approaches.

  • Parkinson's Disease treatments
  • CNS response analysis
  • Cerebral Amyloid Angiopathy

Focus on developing targeted therapies and understanding brain mechanisms.

03 Cancer and Chronic Conditions

Advanced research in oncology and chronic diseases, including studies on gastric cancer imaging and T-cell lymphoma treatments. Investigations into kidney disease management.

  • Advanced solid tumors
  • Gastric cancer diagnosis
  • Chronic kidney disease

Emphasis on innovative diagnostic techniques and treatment approaches.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.